Exact Sciences’ (EXAS) “Neutral” Rating Reaffirmed at BTIG Research

BTIG Research reissued their neutral rating on shares of Exact Sciences (NASDAQ:EXAS) in a research note published on Tuesday,Benzinga reports.

Other analysts have also recently issued reports about the stock. Mizuho restated a “neutral” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Evercore set a $105.00 price objective on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Stifel Nicolaus reissued a “hold” rating and set a $105.00 target price (up from $80.00) on shares of Exact Sciences in a report on Friday, November 28th. Zacks Research downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, TD Cowen lowered Exact Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 25th. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $92.13.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $104.91 on Tuesday. Exact Sciences has a one year low of $38.81 and a one year high of $104.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The business’s fifty day moving average price is $103.17 and its 200-day moving average price is $86.84. The stock has a market capitalization of $20.03 billion, a PE ratio of -95.37, a P/E/G ratio of 2.02 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). The firm had revenue of $878.38 million during the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The company’s revenue was up 23.1% compared to the same quarter last year. During the same period last year, the business posted ($0.06) EPS. On average, equities research analysts anticipate that Exact Sciences will post -0.58 EPS for the current year.

Institutional Trading of Exact Sciences

A number of large investors have recently modified their holdings of the business. Principal Securities Inc. increased its position in shares of Exact Sciences by 3.8% in the fourth quarter. Principal Securities Inc. now owns 3,058 shares of the medical research company’s stock worth $311,000 after purchasing an additional 111 shares during the last quarter. Centaurus Financial Inc. lifted its position in Exact Sciences by 5.0% during the third quarter. Centaurus Financial Inc. now owns 2,517 shares of the medical research company’s stock valued at $138,000 after purchasing an additional 120 shares during the last quarter. Signaturefd LLC grew its stake in Exact Sciences by 5.5% in the 4th quarter. Signaturefd LLC now owns 2,346 shares of the medical research company’s stock worth $238,000 after buying an additional 123 shares in the last quarter. Brookstone Capital Management grew its stake in Exact Sciences by 1.5% in the 4th quarter. Brookstone Capital Management now owns 10,248 shares of the medical research company’s stock worth $1,041,000 after buying an additional 148 shares in the last quarter. Finally, CoreCap Advisors LLC increased its holdings in shares of Exact Sciences by 16.1% in the 4th quarter. CoreCap Advisors LLC now owns 1,086 shares of the medical research company’s stock worth $110,000 after buying an additional 151 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences News Roundup

Here are the key news stories impacting Exact Sciences this week:

• Positive Sentiment: Abbott completed the acquisition of Exact Sciences, a cash takeover reported in the $21–$23 billion range; the deal transfers Cologuard and Exact’s screening business to Abbott, which typically implies a buyout premium for EXAS shareholders. Abbott completes acquisition of Exact Sciences
• Neutral Sentiment: Local reporting confirms the transaction close and reiterates deal valuation (~$23B in some reports); this is corroborating coverage rather than new terms, so it mainly reinforces the takeover rationale. Abbott closes $23 billion deal to buy Madison-based Exact Sciences
• Neutral Sentiment: An alternate outlet reported a $21 billion figure for the transaction — a discrepancy in headlines that can create short‑term price noise but does not change the fact of the acquisition closing. Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover
• Neutral Sentiment: Trading in EXAS was temporarily halted before the announcement for “News pending,” consistent with an imminent corporate action; halts are routine ahead of M&A prints but can amplify intraday volatility.
• Neutral Sentiment: BTIG reiterated a “neutral” rating on EXAS earlier — a hold-type view that is now secondary to the acquisition close, though it may matter for pre-close trading context. BTIG Research reaffirms neutral on Exact Sciences
• Neutral Sentiment: Several short‑interest reports posted odd entries showing 0 shares and NaN changes — this appears to be a data glitch rather than evidence of new shorting activity, so it’s unlikely to be a reliable signal.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.